Skip to main content
Premium Trial:

Request an Annual Quote

DNA Sciences Files for Bankruptcy, Genaissance To Acquire Assets

NEW YORK, April 1 - DNA Sciences said today that it has filed for Chapter 11 bankruptcy in the US Bankruptcy Court for the Northern District of California.


Genaissance Pharmaceuticals plans to acquire the company's assets for around $1.3 million in cash and stock pending bankruptcy court approval for a pre-negotiated asset purchase agreement. The companies expect this approval process to occur within 60 days.


The acquisition of DNA Sciences' technology "would further our goal of building a comprehensive business in drug response pharmacogenomics while maintaining our internal financial benchmarks," said Kevin Rakin, president and CEO of Genaissance. The company expects the acquisition to be cash-flow positive in 2004 and contribute to Genaissance's goal of reaching financial breakeven in 2005.


Further details are available here.


The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.